RT Journal Article
SR Electronic
T1 Low serum vitamin D level and COVID-19 infection and outcomes, a multivariate meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.24.20218974
DO 10.1101/2020.10.24.20218974
A1 Jie Chen
A1 Lixia Xie
A1 Ping Yuan
A1 Jianyong Ma
A1 Peng Yu
A1 Chunhua Zheng
A1 Xiao Liu
YR 2020
UL http://medrxiv.org/content/early/2020/10/27/2020.10.24.20218974.abstract
AB Objective This study aimed to determine whether serum vitamin D is independently associated with COVID-19 infection and outcomes in patients with COVID-19.Methods We identified relevant studies by searching the PubMed, Embase, and medRxiv databases from December 2019 to October 1, 2020. Odds ratios (ORs) were pooled using random-effects models. Only reports with multivariate adjusted results were included to avoid the impact of potential confounding factors.Results A total of six studies with 377,265 patients were identified. Overall, in the categorical analysis, a low serum vitamin D level was associated with an increased risk of COVID-19 infection (OR: 1.47, 95% CI: 1.09- 1.97, I2=81%), hospitalization (OR: 1.83, 95% CI: 1.22-2.74, I2=0%), but not in-hospital death (OR: 2.73, 95% CI: 0.27-27.61). Notably, when vitamin D level was analyzed as a continuous variable, each 5 ng/ml increase in vitamin D level was not associated with any increased risk of COVID-19 infection (OR: 1.04, 95% CI: 0.96-1.12, I2=74%) or in-hospital death (OR: 1.02, 95% CI: 0.93-1.12).Conclusions Low serum vitamin D is associated with an increased risk of COVID-19 infection and hospitalization. In-hospital death showed a tendency to be increased in COVID-19 patients with low vitamin D levels. The ongoing clinical trials for evaluation of vitamin D supplementation will be key to the validation of this adjunctive treatment for COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the National Natural Science Foundation of China (No.81760050, 81760048) and the Jiangxi Provincial Natural Science Foundation for Youth Scientific Research (No. 20192ACBL21037).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data was provided in mansuciptCOVID-19coronavirus disease 2019ORodds ratioCIconfidence intervalIVinverse varianceSEstandard error